Compare Enveric Biosciences Inc (ENVB) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Annaly Capital Management, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Annaly Capital Management, Inc. trades at $18.15 (market cap $13.77B). The key difference: Annaly Capital Management, Inc. is far larger — about 2025× Enveric Biosciences Inc's market cap, and Annaly Capital Management, Inc. pays a 16.42% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Annaly Capital Management, Inc. for 92 Days on average.
| ENVB | NLY | |
|---|---|---|
Market Cap | $6.80M | $13.77B |
Volume | 64,867 | 21,283,879 |
Sector | Health | Real Estate |
52-Week High | $10.80 | $24.40 |
52-Week Low | $1.27 | $17.93 |
Typical Hold Time | 14 Days | 92 Days |
Enterprise Value | -$1.49M | $135.80B |
Dividend Yield | — | 16.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
NLY trades at $18.07, up 0.78% today, with a bearish technical signal despite oversold RSI readings. The stock offers a high dividend yield near 15% and trades below book value (P/B 0.91). Recent quarters show consistent EPS beats, with Q3 2026 results pending. The company's portfolio expansion to $107 billion in 2026 supports earnings growth, though cash flow trends show heavy reliance on financing activities.
The outlook balances high income potential against interest rate sensitivity. Analyst consensus is bullish with a $22 price target, but rising debt-to-asset ratios and mortgage rate volatility pose risks. Sustainable dividend coverage remains key for total return prospects amid market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
